Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Wants Other Firms' Compounds For Mass Pediatric Cancer Screening

Executive Summary

Master protocol for Phase I/II screening trial could make development more efficient, but concerns about regulatory obligations, lack of registrational intent and infrastructure complexity – as well as firms' willingness to share – may be hurdles to participation.

Advertisement

Related Content

Master Protocols In Practice
Pediatric Drug Development A Priority For US FDA’s New Oncology Center Of Excellence
AML Master Protocol For Precision Medicine Developed By Nonprofit And US FDA
FDA Encourages Pediatric Master Protocols With Bayesian Approach
I-SPY 2 Helping To Normalize Adaptive Trial Designs
Rethinking Oncology Development: Master Protocols May Shorten Time To Approval
Lung-MAP Patient Screening Should Translate To Cost-Savings

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS120165

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel